Treatment of Alzheimer's disease with cholinesterase inhibitors.
The cholinergic system is the most severely affected neurotransmitter system in patients with Alzheimer's disease, and therapeutic strategies have been developed to restore cholinergic function in these patients. This article reviews the present status of cholinesterase inhibitors for the treatment of Alzheimer's disease. It then discusses treatment approaches and current and future issues regarding efficacy and safety.
Schneider
L S
LS
Department of Psychiatry and the Behavioral Sciences and Neurology, Keck School of Medicine and the Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California 90033, USA. lschneid@usc.edu
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000855:Anorexia / Q000139:chemically induced; D001919:Bradycardia / Q000139:chemically induced; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods; D005221:Fatigue / Q000139:chemically induced; D005544:Forecasting; D006801:Humans; D012449:Safety; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
D002800:Cholinesterase Inhibitors